4.2 Review

Screening, evaluation and management of depression in people with diabetes in primary care

Journal

PRIMARY CARE DIABETES
Volume 7, Issue 1, Pages 1-10

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.pcd.2012.11.002

Keywords

Diabetes mellitus; Depression; Diabetes distress; Screening; Primary care; Cognitive behavioral therapy

Funding

  1. Eli Lilly
  2. Merck
  3. MSD
  4. Novo Nordisk
  5. Sanofi Aventis
  6. Takeda
  7. Bioton
  8. Servier
  9. NIHR CLAHRC
  10. Boehringer-Ingelheim
  11. Mannkind
  12. Pfizer
  13. Astra Zeneca
  14. Diabetes Research Foundation
  15. Lifescan

Ask authors/readers for more resources

Family physicians are responsible for diagnosing and treating the majority of people with type 2 diabetes mellitus and co-morbid depression. As a result of the impact of co-morbid depression on patient self-care and treatment outcomes, screening for depression in the context of a structured approach to case management and patient follow up is recommended in people with diabetes and cardiovascular disease. This review summarizes the need for improved recognition and treatment of depression in diabetes; and makes expert recommendations with regard to integrating screening tools and therapies into a busy family or general medical practice setting. (C) 2012 Primary Care Diabetes Europe. Published by Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available